Share on StockTwits

Smith & Nephew plc (NYSE:SNN) has received a consensus recommendation of “Hold” from the sixteen brokerages that are presently covering the company, Analyst Ratings News reports. Nine equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $97.00.

Shares of Smith & Nephew plc (NYSE:SNN) opened at 87.345 on Friday. Smith & Nephew plc has a 52 week low of $57.99 and a 52 week high of $100.90. The stock’s 50-day moving average is $87.67 and its 200-day moving average is $82.09. The company has a market cap of $15.617 billion and a price-to-earnings ratio of 30.32. Smith & Nephew plc also was the recipient of a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 394,959 shares, a drop of 38.5% from the July 15th total of 641,725 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 114,135 shares, the days-to-cover ratio is currently 3.5 days.

Smith & Nephew plc (NYSE:SNN) last announced its earnings results on Friday, August 1st. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.08. Analysts expect that Smith & Nephew plc will post $4.21 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Morgan Stanley downgraded shares of Smith & Nephew plc from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 15th. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday, August 4th. Finally, analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday, August 4th.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.